Tuberculosis remains one of the most consequential infectious disease challenges of the modern era, yet its burden is frequently overshadowed by newer pathogens. This landmark GBD 2023 analysis arrives at a critical inflection point — just as global health funding reductions threaten the infrastructure underpinning TB control — making its granular, three-decade assessment of mortality, incidence, and drug resistance particularly consequential for policymakers and clinicians alike.
Drawing on vital registration records, surveillance systems, verbal autopsy data, and minimally invasive tissue sampling across 204 countries and territories from 1990 through 2023, the researchers deployed two sophisticated modeling platforms — the Cause of Death Ensemble model and DisMod-MR 2.1 — to simultaneously estimate TB incidence, prevalence, and mortality stratified by age, sex, HIV co-infection status, and drug-resistance profile. Multidrug-resistant TB (MDR-TB) was tracked as a distinct burden category, and disability-adjusted life-years (DALYs) were calculated to capture both premature death and years lived with disability. A comparative risk assessment framework further attributed proportions of TB burden to alcohol use, smoking, and elevated fasting plasma glucose — three modifiable risk factors with outsized population-level relevance.
The findings arrive amid serious concern that current trajectories fall substantially short of the WHO End TB Strategy's dual targets: a 95% reduction in TB deaths and a 90% reduction in incidence between 2015 and 2035. This systematic analysis provides the most comprehensive pre-disruption baseline available, which will be indispensable for measuring the downstream impact of funding cuts on TB mortality trends. Several important limitations deserve note: modeled estimates in low-vital-registration settings carry wider uncertainty intervals, and the PAF methodology for risk factors assumes population-level causal relationships that observational data cannot fully confirm. Nevertheless, for a disease disproportionately concentrated in high-poverty, high-HIV-burden regions, this represents an editorially significant, potentially paradigm-shaping dataset — one that reframes TB not merely as a persistent endemic challenge but as a preventable catastrophe being actively reversed by funding decisions made in high-income capitals.